The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
201 - Does a letter announcing provincial listing for a drug need to be PAAB'd? The letter will be a direct mailing from the pharmaceutical company to HCPs in the province announcing the listing, reimbursement criteria and indication of the product.
-
A letter announcing provincial listing for a drug is required to undergo preclearance if includes reimbursement criteria/indication. Note that the preclearance exemption under PAAB code section only applies to a formulary listing announcement which is not linked to a therapeutic claim in any way (e.g. an ad containing only the product name and "Now on formulary").
